How the themes are counted
One paper saying "this needs more study" tells you little. 52 separate papers raising the same open question is a finding about the field. The themes below are ordered by how many distinct papers raised them, most first, with "Other open questions" last. We count papers, not sentences, because one long paper can produce a dozen sentences on the same point.
Of the 369 studies in the library, 253 yielded at least one such sentence (455 from open-access full text, 49 from the abstract only). The rest either had no accessible text, or simply did not phrase an open question in a way we could quote without interpreting it — and we would rather miss one than invent one.
- The mechanism is not understood 52
- Measurement, definitions, assays and standardisation 51
- Real-world delivery, cost and access 51
- Who was studied - diversity and generalisability 49
- Biomarker-defined, genetic and clinical subgroups 47
- Follow-up is too short to know if the effect lasts 42
- Bigger samples and independent replication 27
- Specific exposures, drugs and programmes named as worth testing 25
- Whether the association is causal is still open 18
- Long-term safety and harms 14
- The right dose, intensity, frequency and type is unresolved 13
- When in life to intervene 13
- Better treatments and interventions still need developing 2
- Combination and multidomain approaches 1
- Other open questions 35
Where the papers disagree
These are not gaps everyone agrees on. In each pair below, two papers in this library point in different directions about what should happen next. Both quotes are verbatim.
Physical activity: is the open question whether it works, or which kind works best?
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. · BMJ, 2017
“Future studies are needed to confirm current findings, explore the effects of different types of exercise training on outcomes in individuals with SVCI, identify moderators of exercise efficacy (e.g., biological sex), and examine the distinct mechanisms by which each exercise modality may exert its benefits.”
Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial. · Alzheimer's & Dementia, 2026
Both papers are asking for more exercise research, but not the same research. One reports no association with cognitive decline at all; the other treats the benefit as established enough that the next question is which modality and which mechanism.
Vision and hearing: replicate the association first, or start rolling out screening?
“While some US cohort studies have observed a significant association between vision impairment and dementia risk [ , ], other US and European longitudinal studies have failed to replicate these findings [ – ].”
“Future studies should test whether vision screening or cataract surgery in those with co-occurring dementia risk factors are effective at reducing the risk of dementia.”
Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia. · JAMA Network Open, 2024
The same body of evidence is read two ways: one review notes that the vision-dementia association has failed to replicate across cohorts, while the proposed next steps elsewhere assume it holds and move to testing or implementing screening.
Repeat scans and tests to monitor disease: not supported, or the obvious next study?
“Cross‐sectional and longitudinal studies do not support the use of a subsequent amyloid PET to assess the degree of cognitive impairment or to monitor the rate of progression of the underlying AD pathological process.”
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. · Alzheimer's & Dementia, 2025
“Additionally, future research should explore how the test can monitor disease as it progresses or how treatment responds with longitudinal studies [ ] .”
FDA approval of the Lumipulse G PTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis. · Annals of Medicine and Surgery, 2025
The appropriate-use criteria for amyloid and tau PET state that the existing longitudinal evidence does not support repeat amyloid imaging for monitoring. An editorial on the newly approved blood test proposes studying exactly that use for blood biomarkers. Different tests - but the same unresolved question about whether repeat measurement tracks anything useful.
The mechanism is not understood 52 papers
The effect is measurable; the biology behind it is not settled. — 58 quoted sentences from 52 separate papers.
-
“Further study of CAA‐ri may therefore offer a valuable model for exploring the pathophysiological mechanisms of ARIA.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Spontaneous hemorrhages and edema · source text
-
“Though the mechanism remains unclear, ARM may act as a defense against beta-amyloid accumulation through barrier formation and increased phagocytosis.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“Lastly, starting from our results, future studies need to more deeply explore the underlying biological mechanisms through which the MedDiet may influence dementia, and therefore comparing the effectiveness of the MedDiet with other dietary patterns in reducing the risk of dementia.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Implications for policy, practice and future research · source text
-
“Future studies are needed to better elucidate these mechanisms.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“The role of prolonged sleep duration in the development of dementia remains unclear and is closely associated with age.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Sleep duration and cognitive disorders · source text
-
“Further research into the interaction between diet and genetics on dementia risk is therefore warranted.”
— Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition: findings from the UK Biobank prospective cohort study.; Shannon OM, Ranson JM, Gregory S, Macpherson H, Milte C, Lentjes M, et al.; BMC Medicine, 2023. Discussion · source text
Show the other 52 quotes in this theme
Measurement, definitions, assays and standardisation 51 papers
Different teams measuring different things and calling them the same name. — 57 quoted sentences from 51 separate papers.
-
“Though it identified many reasons to involve specialist palliative care, the lack of consensus highlighted the need for further study on a set of consensus referral criteria that may streamline referrals to specialist palliative care in a timely manner to optimize patient and caregiver outcomes.”
— Referral Criteria for Specialist Palliative Care for Patients With Dementia.; Chang YK, Philip J, van der Steen JT, Van den Block L, Hum AYM, Pérez-Cruz PE, Paiva C, Mori M, Chen PJ, Agar MR, et al.; JAMA Network Open, 2025. Introduction · source text
-
“The relative roles of SWI versus GRE for the detection of microhemorrhages warrant further evaluation.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Outstanding challenges and future directions · source text
-
“Future studies should use modeling techniques that can better account for these other types of societal costs.”
— Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060.; Nandi A, Counts N, Bröker J, Malik S, Chen S, Han R, Klusty J, Seligman B, Tortorice D, Vigo D, Bloom DE; npj Aging, 2024. Discussion · source text
-
“Although we found some evidence of differences in hazards for stroke, pneumonia, and acute kidney injury between male and female antipsychotic users, further research is needed to validate these findings.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Strengths and limitations of this study · source text
-
“Future studies should aim to adopt standardized diagnostic frameworks incorporating objective sleep measures (e.g., polysomnography or actigraphy) to minimize variability in sleep disorder definitions.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Publication bias and heterogeneity · source text
-
“If future studies confirm that Aβ positivity affects SAA results, it is then crucial to develop SAA protocols that are robust to Aβ co-pathology.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
Show the other 51 quotes in this theme
Real-world delivery, cost and access 51 papers
Whether a result that held in a trial survives contact with an ordinary clinic. — 52 quoted sentences from 51 separate papers.
-
“Further research is necessary not only to validate their use in the primary and specialist care settings but also to evaluate for possible impediments to effective implementation.”
— Referral Criteria for Specialist Palliative Care for Patients With Dementia.; Chang YK, Philip J, van der Steen JT, Van den Block L, Hum AYM, Pérez-Cruz PE, Paiva C, Mori M, Chen PJ, Agar MR, et al.; JAMA Network Open, 2025. Discussion · source text
-
“Clinicians will need to be prepared to engage in a multistep process of evaluating appropriateness for treatment, with each step involving education and counseling.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review RISK/BENEFIT CONVERSATIONS IN TREATMENT DECISION‐MAKING AND PATIENT PERSPECTIVE · source text
-
“Future studies should use modeling techniques that can better account for these other types of societal costs.”
— Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060.; Nandi A, Counts N, Bröker J, Malik S, Chen S, Han R, Klusty J, Seligman B, Tortorice D, Vigo D, Bloom DE; npj Aging, 2024. Discussion · source text
-
“Further research is needed into safer drug treatment of behavioural and psychological symptoms of dementia and more efficacious, easy to deliver, initial non-drug treatments.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
-
“The next steps will be to establish the most effective, cost-effective, and feasible strategies for reducing these risks, that can be sustained within local contexts and achieve the best impacts, at the population level, in the short, medium, and long term.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Future studies should, where possible, incorporate objective measures of hearing aid benefit—such as aided audiometry, speech-in-noise tests, or even real-world data logging of device use—to validate and extend our findings based on self-report.”
— Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts.; Jiang F, Dong Q, Jayakody DMP, Chen X, Mueller C, Wu B, et al.; Cell Reports Medicine, 2026. Discussion · source text
Show the other 46 quotes in this theme
Who was studied - diversity and generalisability 49 papers
Authors flag that their sample was narrow and that the result may not transfer. — 52 quoted sentences from 49 separate papers.
-
“Overall, the results highlight that interventions will not only need to be tailored to different countries but also to the unique risk profiles and needs of different groups within countries.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Further research across diverse global settings, particularly in low-resource settings, is essential to confirm these findings and guide tailored interventions.”
— Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts.; Jiang F, Dong Q, Jayakody DMP, Chen X, Mueller C, Wu B, et al.; Cell Reports Medicine, 2026. Limitations of the study · source text
-
“The precise underlying causes are uncertain and require further study, extending also to underrepresented regions such as low and middle income countries.”
— Time to nursing home admission and death in people with dementia: systematic review and meta-analysis.; Brück CC, Mooldijk SS, Kuiper LM, Sambou ML, Licher S, Mattace-Raso F, Wolters FJ; BMJ, 2025. meta-analysis Geographical and temporal differences in prognosis · source text
-
“Future work should aim to reproduce our findings with larger, and more representative, diverse samples.”
— APOE and Alzheimer's disease and related dementias risk among 12,221 Hispanics/Latinos.; Barral S, Yang Z, Phillips N, Barber RC, Brickman AM, Honig LS, Cieza B, Reyes-Dumeyer D, Mayeux R, Rajabli F, et al.; Alzheimer's & Dementia, 2025. DISCUSSION · source text
-
“However, future work should validate the test in diverse groups to realize its full clinical use.”
— FDA approval of the Lumipulse G PTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis.; Biruk D. Ayalew, Zemichael G. Alemayehu, Tsimona D. Bonger, Brook L. Sime, Yonatan A. Zewdie, Yeamlak T. Tewodros, Sher Bano; Annals of Medicine and Surgery, 2025. editorial Future directions and recommendations · source text
-
“Finally, this study did not formally assess potential interactions between age, race/ethnicity, sex, neighborhood deprivation, and dementia incidence or prevalence, and future work to disentangle intersectionality in these dimensions is clearly needed.”
— Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study.; Blass B, Ford CB, Soneji S, Zepel L, Rosa TD, Kaufman BG, Mantri S, Li F, Mac Grory B, Xian Y, et al.; BMJ, 2025. Strengths and weaknesses of study · source text
Show the other 46 quotes in this theme
Biomarker-defined, genetic and clinical subgroups 47 papers
Who benefits, not just whether anyone does. — 56 quoted sentences from 47 separate papers.
-
“While the link between APOE ε2 and ARIA risk remains to be elucidated, these observations suggest that APOE ε2 status may need to be factored into individual risk assessment of hemorrhagic complications following ATTs.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Role of immune responses, CAA‐ri, and APOE genotype · source text
-
“Furthermore, the ARM response is reduced in the setting of sporadic AD genetic risk variants such as TREM2 R47H and APOE E4. While it is plausible that the ARM response to beta-amyloid plaques is protective, the precise mechanism remains unclear.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“In this respect, further research is needed to assess differences between the two sexes in elderly people.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Discussion · source text
-
“If future studies confirm that Aβ positivity affects SAA results, it is then crucial to develop SAA protocols that are robust to Aβ co-pathology.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Overall, the results highlight that interventions will not only need to be tailored to different countries but also to the unique risk profiles and needs of different groups within countries.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Sex and gender differences should be carefully considered in future studies examining the association or effect of olive oil on cognitive-related outcomes to improve our understanding.”
— Consumption of Olive Oil and Diet Quality and Risk of Dementia-Related Death.; Tessier AJ, Cortese M, Yuan C, Bjornevik K, Ascherio A, Wang DD, Chavarro JE, Stampfer MJ, Hu FB, Willett WC, et al.; JAMA Network Open, 2024. Discussion · source text
Show the other 50 quotes in this theme
Follow-up is too short to know if the effect lasts 42 papers
Papers repeatedly say their own follow-up window cannot answer whether a benefit persists. — 51 quoted sentences from 42 separate papers.
-
“In fact, longitudinal studies may be prone to selection bias, especially in the elderly population, who may be lost to follow-up for various reasons, including death.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Discussion · source text
-
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
— Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.; Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, Singh-Manoux A; BMJ, 2017. Strengths and limitations of study · source text
-
“Many studies of cognitive impairment due to RBD and circadian rhythm are extremely small for a comprehensive evaluation, and further longitudinal studies are warranted in the future.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Other sleep disorders and cognitive disorders · source text
-
“Future studies may benefit from strategies to support sustained engagement, such as enhanced technical support and additional check-ins to address challenges.”
— Digital Reminiscence for Predeath Grief Among Family Caregivers of Patients With Dementia: A Pilot Randomized Clinical Trial.; Falzarano FB, Greenfield A, Saviano SC, Kolla S, Korian S, Osso F, Miller J, Whitson HE, Maciejewski PK, Prigerson HG; JAMA Network Open, 2026. randomised controlled trial Discussion · source text
-
“The next steps will be to establish the most effective, cost-effective, and feasible strategies for reducing these risks, that can be sustained within local contexts and achieve the best impacts, at the population level, in the short, medium, and long term.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Although we acknowledge that this was a 12-month-duration study, which may be insufficient to definitively establish long-term clinical benefit in Alzheimer’s disease, it can still yield meaningful insights, and further studies are necessary to fully establish the effectiveness of this drug.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
Show the other 45 quotes in this theme
-
“Some longitudinal studies have also demonstrated beneficial effects of APOE2 and deleterious effects of APOE4 on longevity ( ; ).”
— APOE2 is associated with longevity independent of Alzheimer's disease.; eLife, 2020. Introduction
-
“Consequently, larger longitudinal studies are needed to elucidate to what extent the presence of LB pathology exacerbates AD-related cognitive decline and associated regional neuronal dysfunction.”
— Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer's disease.; Nature Communications, 2024. Introduction
-
“While some US cohort studies have observed a significant association between vision impairment and dementia risk [ , ], other US and European longitudinal studies have failed to replicate these findings [ – ].”
— A comprehensive evaluation on the associations between hearing and vision impairments and risk of all-cause and cause-specific dementia: results from cohort study, meta-analysis and Mendelian randomization study.; BMC Medicine, 2024. Background
-
“Additionally, future research should explore how the test can monitor disease as it progresses or how treatment responds with longitudinal studies [ ] .”
— FDA approval of the Lumipulse G PTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis.; Annals of Medicine and Surgery, 2025. Future directions and recommendations
-
“However, we cannot confirm that the COVID-19 pandemic caused the lower association observed through follow-up to 2022. Further study will help clarify the association of COVID-19 with early diagnosis of dementia.”
— Annual Wellness Visits and Early Dementia Diagnosis Among Medicare Beneficiaries.; JAMA Network Open, 2024. Discussion
-
“Future work to probe the mechanisms behind observed differences seen by sex, race/ethnicity, and neighborhood socioeconomic status could be conducted through analysis of longitudinal cohort studies with information on both cognitive outcomes and detailed life course history.”
— Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study.; BMJ, 2025. Unanswered questions and future research
-
“Finally, self‐ or proxy‐reported dementia diagnosis may reflect limited awareness rather than the absence of a diagnosis, a factor that may itself carry prognostic relevance. , Future studies should examine patient‐centered outcomes, including quality of life and functional trajectories, to better characterize the impact of undiagnosed dementia on older adults.”
— Undiagnosed dementia and mortality among older adults in the United States and Brazil: A cross-national cohort study.; Alzheimer's & Dementia, 2026. DISCUSSION
-
“However, this model remains speculative and requires validation through longitudinal studies, functional assays, and experimental models.”
— Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIA.; Nature Communications, 2026. Discussion
-
“Meta-analyses of longitudinal studies [ , ] and studies published after these searches were completed for these meta-analyses (since May 2017) [ – ] have reported greater dementia risk and worse cognition [ ] in those with less frequent social contact.”
— Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study.; PLoS Medicine, 2019. Introduction
-
“Cross‐sectional and longitudinal studies do not support the use of a subsequent amyloid PET to assess the degree of cognitive impairment or to monitor the rate of progression of the underlying AD pathological process.”
— Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.; Alzheimer's & Dementia, 2025. Amyloid
-
“Although the key methods were identical, CFAS I was a two-stage study whereas CFAS II was one-stage, a decision made on the basis of experience of both attrition between phases and complexity of analysis in longitudinal studies.”
— A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II.; The Lancet, 2013. Discussion
-
“Although a recent review assessed prospective longitudinal studies to describe the associations between CR, AD biomarkers, and cognitive/clinical outcomes in participants who were cognitively normal at baseline (i.e., preclinical AD-dementia) (Soldan et al. ), their focus on how CR was related to multiple outcomes including onset of clinical symptoms of MCI, changes in cognition, and changes in AD biomarkers, precluded a quantitative examination and limited conclusions regarding the effect of CR on dementia progression.”
— Cognitive Reserve, Alzheimer's Neuropathology, and Risk of Dementia: A Systematic Review and Meta-Analysis.; Neuropsychology Review, 2021. Focus of the Current Review
-
“It is unknown whether discontinuation of long-term antipsychotic medications in this population can improve clinical outcomes.”
— Clinical outcomes after antipsychotic discontinuation in nursing home residents with dementia: a nationwide cohort study.; Alzheimer's Research & Therapy, 2026. abstract only
-
“Further research should examine patterns of expenditures in later years and around critical timepoints in caregiving, such as partner transitions to formal long-term care settings and death, to better understand healthcare expenditures for spouses of persons living with dementia.”
— Medicare expenditures among spouses of persons with dementia.; Journal of the American Geriatrics Society, 2024. abstract only
-
“After incorporating 48 longitudinal studies involving 103,651 participants, a moderate-to-high level of evidence suggested that dietary intake of omega-3 fatty acids could lower risk of all-cause dementia or cognitive decline by ∼20%, especially for docosahexaenoic acid (DHA) intake (relative risk [RR]: 0.82, I2 = 63.6%, P = 0.001) and for studies that were adjusted for apolipoprotein APOE ε4 status (RR: 0.83, I2 = 65%, P = 0.006).”
— The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers.; American Journal of Clinical Nutrition, 2023. abstract only
-
“Previous randomized controlled trials and longitudinal studies have indicated that ongoing antihypertensive use in late life reduces all-cause dementia risk, but the specific impact on Alzheimer dementia (AD) and non-AD risk remains unclear.”
— Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis.; Neurology, 2024. abstract only
-
“The risk estimates were lower than in previous studies, highlighting the need for more high-quality longitudinal studies.”
— Hearing Loss, Hearing Aid Use, and Risk of Dementia in Older Adults.; JAMA Otolaryngology-Head & Neck Surgery, 2024. abstract only
-
“As mentioned before, longitudinal studies among the elderly might be biased because of the potentially high number of lost to follow-up.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Aging Clinical and Experimental Research, 2024. Limitations and strengths
-
“Secondly, the conclusions from some longitudinal studies do not differentiate findings on cognitive performance from those on cognitive decline.”
— Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.; BMJ, 2017. Comparison with other studies
-
“Longer observation periods and longitudinal studies are warranted to evaluate the association between reduced rate of hippocampal atrophy and protective effects on cognition, such as memory and other clinically relevant domains.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Nature Medicine, 2025. Discussion
-
“Serial assessment during early infusions could identify evolving risk before radiographic ARIA appears, though whether such changes predict radiographic ARIA or simply correlate with it remains to be determined in longitudinal studies.”
— Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIA.; Nature Communications, 2026. Discussion
-
“One recent feasibility study examined the effect of daily internet-based conversational interactions on cognitive decline in people with mild cognitive impairment, finding better verbal fluency at 12-week follow-up in those who received the intervention compared to the control group [ ], and future studies should examine the feasibility of increasing social contact and its effect on cognition and dementia risk with longer follow-up.”
— Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study.; PLoS Medicine, 2019. Clinical implications and future research
-
“However, the use of tau PET in this scenario is currently being prospectively validated, and additional longitudinal studies are needed to further elucidate the prognostic value of tau PET in MCI.”
— Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.; Alzheimer's & Dementia, 2025. Tau
-
“Further studies of amyloid and tau PET in underrepresented populations are underway, as are efforts to enhance diversity across longitudinal AD and related disorders research cohorts.”
— Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.; Alzheimer's & Dementia, 2025. LIMITATIONS OF EVIDENCE REVIEW
-
“Beyond their diagnostic value, future work will undoubtedly focus on whether amyloid and tau PET can identify optimal responders to various treatments and whether the duration of treatment can be calibrated on the basis of longitudinal changes in PET.”
— Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.; Alzheimer's & Dementia, 2025. FURTHER RESEARCH QUESTIONS
-
“Thus, future studies should examine whether representing CR with environmental factors that can change over time (e.g., social or intellectual engagement, change in cognitive function) strengthen or weaken the CR-AD neuropathology-dementia progression interaction.”
— Cognitive Reserve, Alzheimer's Neuropathology, and Risk of Dementia: A Systematic Review and Meta-Analysis.; Neuropsychology Review, 2021. Implications and Future Research
-
“Longitudinal studies with extended follow-up periods are needed to better characterize the natural history of LATE and its interplay with coexisting AD and other pathologies.”
— Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic; Neurology, 2026. discussion
-
“Finally, due to the lack of longitudinal plasma biomarker data, we were unable to determine if changes in plasma biomarker levels over time are better indicators of developing Aβ pathology.”
— Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment; JAMA Neurology, 2024. discussion
-
“It is possible that our model has underestimated the cumulative health benefits and cost effectiveness of lecanemab, and it is important to update the model to incorporate a longer time horizon as more follow-up data from SveDem become available.”
— The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden; PharmacoEconomics, 2025. discussion
-
“Future analyses will also examine longitudinal experiences in “near-misses” and negative events including physical harm or emotional stress due (e.g. agitation, arguments) related to firearm access reduction.”
— The Effect of the "Safety in Dementia" Online Tool to Assist Decision Making for Caregivers of Persons With Dementia and Access to Firearms: A Randomized Trial; Annals of Internal Medicine, 2024. discussion
-
“The small improvement in apathy after 6 weeks with intermittent dosing is a promising indicator of likely usefulness over longer durations, which could be explored in future phase 3 or pragmatic trial designs.”
— Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial; The Lancet Neurology, 2025. discussion
-
“Assessing slowing of clinical progression in AD with treatment over a longer time interval, such as from long-term real-world evidence, may yield a more clinically relevant NNT.”
— Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial; Neurology: Clinical Practice, 2026. discussion
-
“Future studies should explore how these metrics evolve from normal cognition to MCI to dementia, evaluate their predictive validity in diverse populations, and test interventions to prolong safe driving through tailored education or support.”
— Association of Daily Driving Behaviors With Mild Cognitive Impairment in Older Adults Followed Over 10 Years; Neurology, 2025. conclusion
-
“Future work should leverage longitudinal data to further explore the clinical meaningfulness of these proteomic disease subgroups.”
— A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia; Nature medicine, 2026. discussion
-
“For example, longitudinal research with longer follow‐up is needed to assess whether medical linkage leads to timely diagnosis and treatment initiation.”
— Efficacy of a language-concordant community health worker intervention to improve community-to-clinic linkage for dementia care: results of the randomized trial PLAN; Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. discussion
-
“To address this point and to investigate the long‐term (24 weeks) efficacy and safety of brexpiprazole in Japanese patients with AAD, an extension study was conducted.”
— Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study; Alzheimer's & Dementia, 2024. discussion
-
“As such, we are unable to determine longer-term effects of herpes zoster vaccination on dementia incidence.”
— Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments; The Lancet Neurology, 2026. discussion
-
“Further high-quality cohort studies with follow-ups longer than 10 to 20 years, fine-grained measures of physical activity and cognition at baseline, and high participation and follow-up rates are needed to solidify the evidence base in this area.”
— Physical Activity and Cognitive Decline Among Older Adults: A Systematic Review and Meta-Analysis; JAMA Network Open, 2024. conclusion
-
“Further studies measuring Aβ, tau and GFAP biomarkers at multiple time points with long follow-up durations are needed to confirm the temporal order of appearance of each biomarker abnormality and to determine other possible factors associated with early astrocyte reactivity in preclinical AD.”
— Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease; Nature Medicine, 2023. discussion
-
“Understanding the possible effects of hearing intervention on populations at decreased risk for cognitive decline will require longer-term follow-up of the de novo cohort beyond 3 years which is currently underway.”
— Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial; The Lancet, 2023. discussion
-
“Continued monitoring of trends in dementia incidence and prevalence will be important for better gauging the full future societal impact of dementia as the number of older adults increases in the decades ahead, as well as for clarifying potential protective and risk factors for cognitive decline.”
— A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012; JAMA Internal Medicine, 2017. discussion
-
“Our cohort had an adequate follow-up time (4.7 years on average); however, we cannot exclude that at a longer follow-up a similar association could be observed.”
— Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment; Alzheimer's Research & Therapy, 2021. discussion
-
“At the same time, we were unable to assess the trajectories of these markers over time and how that relates to their associations with dementia outcomes and overall utility.”
— Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health study; Alzheimer's & Dementia, 2023. discussion
-
“Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer's disease.”
— Lecanemab in Early Alzheimer's Disease; New England Journal of Medicine, 2023. abstract only
-
“Further investigation of functional outcomes, biomarkers, and ongoing extended follow-up will help address clinical relevance and sustainability of the observed cognitive benefits.”
— Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial; JAMA, 2025. abstract only
Bigger samples and independent replication 27 papers
More people, and someone else repeating it. — 27 quoted sentences from 27 separate papers.
-
“Due to the exploratory nature of this phase 2b study, these findings need to be confirmed in larger studies.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
-
“However, whether the latter was more pronounced in women than in men was not examined and requires further investigation by future studies that are adequately powered to detect sex differences.”
— Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia.; Chatterjee S, Peters SAE, Woodward M, et al.; Diabetes Care, 2016. meta-analysis Conclusions · source text
-
“While some US cohort studies have observed a significant association between vision impairment and dementia risk [ , ], other US and European longitudinal studies have failed to replicate these findings [ – ].”
— A comprehensive evaluation on the associations between hearing and vision impairments and risk of all-cause and cause-specific dementia: results from cohort study, meta-analysis and Mendelian randomization study.; Jiang F, Dong Q, Wu S, Liu X, Dayimu A, Liu Y, Ji H, Wang L, Liu T, Li N, et al.; BMC Medicine, 2024. meta-analysis Background · source text
-
“Therefore, future studies with larger numbers of vascular dementia cases are needed.”
— Dose-response association between device-measured physical activity and incident dementia: a prospective study from UK Biobank.; Petermann-Rocha F, Lyall DM, Gray SR, Gill JMR, Sattar N, Welsh P, et al.; BMC Medicine, 2021. Strengths and limitations · source text
-
“Further studies using larger numbers of well-characterized AD patients and neuropathological data will thus be required to more precisely delineate the impact of each of the loci on AD pathology versus other neuropathologies.”
— Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementias.; Bellenguez C, Lambert JC, et al.; Nature Genetics, 2026. meta-analysis Main · source text
Show the other 22 quotes in this theme
Specific exposures, drugs and programmes named as worth testing 25 papers
Where authors do not just say 'more research' but name the thing they think should be tested. — 31 quoted sentences from 25 separate papers.
-
“While red wine, a key contributor of anthocyanin intake, has been shown to be beneficial for both dementia and depression at moderate intakes, , the associations among alcohol intake, depression, and dementia are complex, and future studies are needed to further understand these findings.”
— Flavonoid-Rich Foods, Dementia Risk, and Interactions With Genetic Risk, Hypertension, and Depression.; Jennings A, Thompson AS, Tresserra-Rimbau A, O'Neill JK, Hill C, Bondonno NP, et al.; JAMA Network Open, 2024. Discussion · source text
-
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
— Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.; Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, Singh-Manoux A; BMJ, 2017. Strengths and limitations of study · source text
-
“The role of prolonged sleep duration in the development of dementia remains unclear and is closely associated with age.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Sleep duration and cognitive disorders · source text
-
“Further research is needed to investigate semaglutide's effects in patients with obesity, both with and without T2DM.”
— Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.; Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“However, this previous analysis was not designed to examine the association of olive oil and diet quality with dementia-related mortality, and therefore the latter remains unclear.”
— Consumption of Olive Oil and Diet Quality and Risk of Dementia-Related Death.; Tessier AJ, Cortese M, Yuan C, Bjornevik K, Ascherio A, Wang DD, Chavarro JE, Stampfer MJ, Hu FB, Willett WC, et al.; JAMA Network Open, 2024. Introduction · source text
-
“Future studies should evaluate the influence of suddenly stopping the GLP-1 analogs on the brain after daily injections for a year.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
Show the other 25 quotes in this theme
Whether the association is causal is still open 18 papers
Observational signals that the authors themselves decline to call cause and effect. — 18 quoted sentences from 18 separate papers.
-
“Although the analyses were adjusted for the number of components the participants received, future studies could consider testing intervention components with similar dosage and delivery settings to minimize confounding factors.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Strengths and Limitations · source text
-
“Future studies will need to confirm underlying mechanisms and should investigate other eye diseases (observationally and in MR studies), including diabetic retinopathy, optic neuropathy, and other vascular causes of eye disease.”
— Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.; Ferguson EL, Thoma M, Buto PT, Wang J, Glymour MM, Hoffmann TJ, et al.; JAMA Network Open, 2024. Discussion · source text
-
“Randomized controlled trials are needed to confirm the observational evidence.”
— Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study.; Wu CY, Alkabbani W, Shah BR, Kapral MK, Edwards JD, Maxwell CJ, et al.; Alzheimer's Research & Therapy, 2025. Limitations · source text
-
“The study findings need to be interpreted keeping in mind the observational nature of the data.”
— Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study.; Sabia S, Fayosse A, Dumurgier J, Dugravot A, Akbaraly T, Britton A, Kivimäki M, Singh-Manoux A; BMJ, 2018. Strengths and limitations of this study · source text
-
“These considerations highlight the need for further research using more rigorous methodologies, such as phase 2 randomized controlled trials with lower attrition and alternative strategies to mitigate assessment‐related biases.”
— A randomized trial of two online platforms for dementia family caregivers: GamePlan4Care and Resources4Care.; Stevens AB, Cho J, Birchfield T, Reese J, Han G, Thorud JL, Ory MG; Alzheimer's & Dementia, 2025. randomised controlled trial DISCUSSION · source text
-
“The cognitive benefits of cataract surgery should be investigated further in randomized trials.”
— Cataract Surgery and Cognitive Benefits in the Older Person: A Systematic Review and Meta-analysis.; Yeo BSY, et al.; Ophthalmology, 2024. meta-analysis abstract only
Show the other 12 quotes in this theme
Long-term safety and harms 14 papers
Adverse effects over a horizon longer than the trial. — 24 quoted sentences from 14 separate papers.
-
“Further study of CAA‐ri may therefore offer a valuable model for exploring the pathophysiological mechanisms of ARIA.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Spontaneous hemorrhages and edema · source text
-
“Whether the microglial response is harmful, helpful, or both during disease progression remains unclear.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“Any potential benefits of antipsychotic treatment therefore need to be weighed against the risk of serious harm across multiple outcomes.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
-
“However, the reported variability in sensitivity and specificity values across our 4 laboratories and fair agreement suggest that the next step is to propose international recommendations for the harmonization of the α-syn SAA for clinical use.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Future studies should report more transparently on the impact of ARIA.”
— Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.; Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, et al.; Cochrane Database of Systematic Reviews, 2026. meta-analysis Implications for research · source text
-
“Although we observed some harmful effects of APOE4 on lifespan, as observed in ‘the early survival’ and median age at death, which many previous longevity studies primarily evaluate ( ), further studies would be needed to confirm that APOE4 has indeed worse impacts on overall lifespan, compared to APOE3 , as observed in clinical data.”
— APOE2 is associated with longevity independent of Alzheimer's disease.; Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, Fryer JD, Heckman MG, Bu G; eLife, 2020. Discussion · source text
Show the other 18 quotes in this theme
The right dose, intensity, frequency and type is unresolved 13 papers
Especially for exercise, diet and other behavioural interventions: something works, but not how much of it. — 15 quoted sentences from 13 separate papers.
-
“However, it remains unclear which specific components or combinations are most effective.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Introduction · source text
-
“Of note, some of the higher‐dose cohorts received a single dose of dexamethasone prior to each treatment to minimize infusion reactions; it remains unknown whether this pre‐treatment has any effect on ARIA occurrence, as lower ARIA rates were also observed among participants who did not receive any steroid pre‐treatment.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Brainshuttle · source text
-
“Future studies are needed to confirm current findings, explore the effects of different types of exercise training on outcomes in individuals with SVCI, identify moderators of exercise efficacy (e.g., biological sex), and examine the distinct mechanisms by which each exercise modality may exert its benefits.”
— Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial.; Liu-Ambrose T, Falck RS, Dao E, Crockett RA, Barha CK, Silva NCBS, et al.; Alzheimer's & Dementia, 2026. randomised controlled trial DISCUSSION · source text
-
“Further studies should be carried out adopting a more rigorous methodology (e.g., randomization strategies) to investigate the effectiveness of COTs, especially CT and CR interventions, and attempting to address the existing heterogeneity, including standardizing interventions, and reporting detailed data on treatment protocols and on the frequency and intensity of interventions.”
— The efficacy of cognitive stimulation, cognitive training, and cognitive rehabilitation for people living with dementia: a systematic review and meta-analysis.; Paggetti A, Druda Y, Sciancalepore F, Della Gatta F, Ancidoni A, Locuratolo N, et al.; GeroScience, 2024. meta-analysis Future directions · source text
-
“However, the current evidence falls short in elucidating the precise dose–response relationship between PA and the incidence of dementia, necessitating further research [ ].”
— Dose- and pattern- physical activity is associated with lower risk of dementia.; Wang Y, Li F, Cao S, Jia J; Journal of Prevention of Alzheimer's Disease, 2025. Introduction · source text
-
“Beyond their diagnostic value, future work will undoubtedly focus on whether amyloid and tau PET can identify optimal responders to various treatments and whether the duration of treatment can be calibrated on the basis of longitudinal changes in PET.”
— Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.; Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, et al.; Alzheimer's & Dementia, 2025. systematic review FURTHER RESEARCH QUESTIONS · source text
Show the other 9 quotes in this theme
When in life to intervene 13 papers
Midlife, preclinical, or after symptoms - the window is contested. — 13 quoted sentences from 13 separate papers.
-
“Future studies should also consider 3‐5 years of long‐term follow‐up, starting from prodromal DLB (mild cognitive impairment with Lewy bodies MCI‐LB), to provide comprehensive coverage of long‐term observations.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“Although we observed some harmful effects of APOE4 on lifespan, as observed in ‘the early survival’ and median age at death, which many previous longevity studies primarily evaluate ( ), further studies would be needed to confirm that APOE4 has indeed worse impacts on overall lifespan, compared to APOE3 , as observed in clinical data.”
— APOE2 is associated with longevity independent of Alzheimer's disease.; Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, Fryer JD, Heckman MG, Bu G; eLife, 2020. Discussion · source text
-
“Future studies in larger community‐based settings may provide additional information on the utility of p‐tau217 in screening for preclinical AD.”
— Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis.; Mohammad Khalafi, William J. Dartora, Laura Beth J. McIntire, Tracy A. Butler, Krista M. Wartchow, Seyed Hani Hojjati, Qolamreza R. Razlighi, Kiarash Shirbandi, Liangdong Zhou, Kewei Chen, Ke Xi, Samprit Banerjee, Nancy Foldi, Silky Pahlajani, Lidia Glodzik, Yi Li, Mony J. de Leon, Gloria C. Chiang; Alzheimer's & Dementia, 2024. meta-analysis Conclusion · source text
-
“Although a recent review assessed prospective longitudinal studies to describe the associations between CR, AD biomarkers, and cognitive/clinical outcomes in participants who were cognitively normal at baseline (i.e., preclinical AD-dementia) (Soldan et al. ), their focus on how CR was related to multiple outcomes including onset of clinical symptoms of MCI, changes in cognition, and changes in AD biomarkers, precluded a quantitative examination and limited conclusions regarding the effect of CR on dementia progression.”
— Cognitive Reserve, Alzheimer's Neuropathology, and Risk of Dementia: A Systematic Review and Meta-Analysis.; Nelson ME, Jester DJ, Petkus AJ, Andel R; Neuropsychology Review, 2021. meta-analysis Focus of the Current Review · source text
-
“Midlife depression has been associated with an increased risk of dementia, but it remains unclear whether this risk is attributable to specific symptoms.”
— Specific midlife depressive symptoms and long-term dementia risk: a 23-year UK prospective cohort study.; Frank P, Singh-Manoux A, Pentti J, Batty GD, Sommerlad A, Steptoe A, et al.; Lancet Psychiatry, 2025. abstract only
Show the other 8 quotes in this theme
Better treatments and interventions still need developing 2 papers
Not whether a thing works, but that no good enough option exists yet. — 2 quoted sentences from 2 separate papers.
-
“Further research is needed into safer drug treatment of behavioural and psychological symptoms of dementia and more efficacious, easy to deliver, initial non-drug treatments.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
Show the other 1 quote in this theme
Combination and multidomain approaches 1 paper
Whether interventions add up, and which ones to combine. — 1 quoted sentence from 1 separate paper.
-
“However, it remains unclear which specific components or combinations are most effective.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Introduction · source text
Other open questions 35 papers
Verbatim suggestions that did not fall into any theme above. They are published rather than discarded so the page does not quietly lose a question an author actually raised. — 47 quoted sentences from 35 separate papers.
-
“While these findings suggest that postmortem CSF SAA results may generally be comparable to those obtained from antemortem samples, further research is needed to fully understand the differences.”
— Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification.; Mastenbroek SE, Collij LE, Vogel JW, Caldera S, Serrano GE, Adler CH, Vargiu CM, Palmqvist S, Barkhof F, Parchi P, et al.; Nature Communications, 2025. Discussion · source text
-
“These factors should be considered in future studies for a more comprehensive evaluation.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“Our report pointing at technical variation in α-syn preparation, experimental conditions, and analysis of SAA results may elucidate several areas for improvement in future studies.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Other biomarkers that seem to be more aligned with tau aggregate pathology – including p-tau262 and p-tau356 for soluble tau assemblies [ ] and MTBR tau for fibrils and tangles [ , ] should be investigated in future studies.”
— Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.; Rebecca A. Deek, Wasiu G. Balogun, Xuemei Zeng, Gallen Triana-Baltzer, Tharick A. Pascoal, Hartmuth C. Kolb, Beth Snitz, Ann D. Cohen, Thomas K. Karikari; Alzheimer's Research & Therapy, 2026. Discussion · source text
-
“Other factors underlying this finding should be explored in future studies.”
— Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.; Sebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, Andrea Pilotto, and colleagues (multi-site Swedish, Spanish and Italian collaboration); Nature Medicine, 2025. Discussion · source text
-
“Though we observed a significant reduction in AD risk in a high‐risk population with T2DM and also high comorbidity (43% obesity and 77% hypertension), future studies should explore longer follow‐ups and different populations.”
— Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.; Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R; Alzheimer's & Dementia, 2024. DISCUSSION · source text